<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838938</url>
  </required_header>
  <id_info>
    <org_study_id>FINBA_critlab_4</org_study_id>
    <nct_id>NCT04838938</nct_id>
  </id_info>
  <brief_title>Personalized Medicine in Patients With Infective Endocarditis</brief_title>
  <official_title>Personalized Medicine in Patients With Infective Endocarditis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación para la Investigación Biosanitaria del Principado de Asturias</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación para la Investigación Biosanitaria del Principado de Asturias</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The hypothesis underlying this work is the identification of different sub phenotypes of&#xD;
      patients with infective endocarditis through the study of the host's response to infection.&#xD;
&#xD;
      Furthemore, metagenomic sequencing may be a helpful supplement to IE diagnostic, especially&#xD;
      when conventional tests fail to yield a diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Infective endocarditis is a life-threatening infection of heart valves and adjacent&#xD;
      structures characterized by vegetations on valves and other endocardial surfaces, with tissue&#xD;
      destruction and risk of embolization.&#xD;
&#xD;
      The clinical variability, including the heterogeneous response to infection and the different&#xD;
      antibiotic treatments make the identification of the underlying pathogens of infective&#xD;
      endocarditis (IE) is critical for precision therapy. Virulence factors mediate tissue&#xD;
      adherence, host infiltration, immune resistance/evasion, and dynamic stress responses and&#xD;
      confer enhanced pathogen survival, proliferation, and host invasion in animal models of&#xD;
      infective endocarditis.&#xD;
&#xD;
      To identify the microorganism and simultaneously considered the response of the host to the&#xD;
      infection could improve the management of the infective endocarditis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>To characterize a cohort of patients diagnosed with infective endocarditis</measure>
    <time_frame>2 year</time_frame>
    <description>Clinical, microbiological and echocardiographic description of patients with infective endocarditis.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Identification of the underlying pathogens of infective endocarditis (IE)</measure>
    <time_frame>2 year</time_frame>
    <description>We will employ next-generation sequencing for pathogens and antimicrobial resistance detection in IE patients.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Host response classification for infective endocarditis (IE)</measure>
    <time_frame>2 year</time_frame>
    <description>Differential baseline expression of some genes may indicate resilience to infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Host response predictors of sepsis outcomes</measure>
    <time_frame>2 year</time_frame>
    <description>We will develop and use advanced bioinformatic, metabolomic, proteomic and mRNA sequencing technologies to identify specific changes, or biomarkers, in patient blood samples that predict outcome in sepsis.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Infective Endocarditis</condition>
  <condition>Response, Acute Phase</condition>
  <condition>Treatment</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Samples with DNA for the study of the host's sub phenotypes Plasma and heart valves to make a&#xD;
      metagenomic sequencing&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with an active infective endocarditis&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of active infective endocarditis according to the modified Duke criteria.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Guillermo Muñiz Albaiceta, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>HUCA-FINBA, Universidad de Oviedo</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raquel Rodríguez-García, MD, PhD</last_name>
    <phone>985652433</phone>
    <email>rrg@crit-lab.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Universitario Central de Asturias</name>
      <address>
        <city>Oviedo</city>
        <state>Principado De Asturias</state>
        <zip>33011</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raquel Rodríguez-García, MD</last_name>
      <phone>985652433</phone>
      <email>rrg@crit-lab.org</email>
    </contact>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>April 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>April 6, 2021</last_update_submitted>
  <last_update_submitted_qc>April 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endocarditis, Bacterial</mesh_term>
    <mesh_term>Endocarditis</mesh_term>
    <mesh_term>Acute-Phase Reaction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All datasets underlying the study are available upon request to the study principal investigator.&#xD;
All of the individual participant data collected during the trial, informed consent forms, study protocol, statistical analysis plan and raw data, are available under reasonable request, and after deindentification.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Starting 3 month after publication</ipd_time_frame>
    <ipd_access_criteria>Principal investigator will review requests of data to be provided.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

